Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Luise Tittl"'
Autor:
Christina Köhler, Luise Tittl, Ulrike Hänsel, Evelyn Hammermüller, Sandra Marten, Christiane Naue, Marianne Spindler, Laura Stannek, Kristina Fache, Jan Beyer-Westendorf
Publikováno v:
TH Open, Vol 07, Iss 03, Pp e251-e261 (2023)
Background Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism (VTE) treatment or stroke prevention in atrial fibrillation. Major surgical procedures are not uncommon in anticoagulated patients but data
Externí odkaz:
https://doaj.org/article/43c89c41fa64416fb4b363d67f8ad1e0
Autor:
Stephanie Müller, Luise Tittl, Victoria Speed, Lara Roberts, Jignesh Patel, Raj Patel, Roopen Arya, Nils Kucher, David Spirk, Kurtulus Sahin, Jan Beyer‐Westendorf
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 7, Pp n/a-n/a (2022)
Abstract Background The direct factor Xa inhibitor rivaroxaban is approved for the treatment of venous thromboembolism (VTE), based on the results of large phase III trials. Objectives To confirm rivaroxaban's effectiveness and safety in routine clin
Externí odkaz:
https://doaj.org/article/10425b55e6f3457b85d480dca2bc05c9
Autor:
Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, Christina Köhler, Luise Tittl, Martin Bornhäuser
Publikováno v:
Thrombosis Update, Vol 5, Iss , Pp 100070- (2021)
Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism treatment or stroke prevention in atrial fibrillation. Effectiveness and safety of edoxaban depends on adequate dosing, for which renal function, body
Externí odkaz:
https://doaj.org/article/35541132159c45f08629d203c95a5c3c
Publikováno v:
TH Open, Vol 05, Iss 02, Pp e143-e151 (2021)
The effectiveness and safety of venous thromboembolism (VTE) treatment with apixaban, demonstrated in phase III trials, need to be confirmed in daily care. Using data from the prospective, noninterventional cross-indication Dresden NOAC Registry we e
Externí odkaz:
https://doaj.org/article/2282bef639334a1e89e4e3281edb7a42
Autor:
Christina, Köhler, Luise, Tittl, Sandra, Marten, Christiane, Naue, Marianne, Spindler, Laura, Stannek, Kristina, Fache, Jan, Beyer-Westendorf
Publikováno v:
Thrombosis Research. 215:37-40
Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for stroke prevention in atrial fibrillation (SPAF). Outcome data on clinical effectiveness and safety in routine care are increasing.In the prospective, non-interventional DRES
Publikováno v:
Thrombosis Research. 202:24-30
Introduction Following successful phase-III trials, direct oral anticoagulants such as rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF). However, data from randomized trials should be confirmed in unselec
Autor:
Bettina Kemkes-Matthes, Ingrid M. Bistervels, WE Paulus, Sandra Marten, Martin Bornhäuser, Luise Tittl, Saskia Middeldorp, Jan Beyer-Westendorf, Christof Schaefer, Will Thomas
Publikováno v:
Lancet. Haematology, 7(12), e884-e891. Lancet Publishing Group
Summary Background Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists in many indications for anticoagulation. Prescribed to millions of patients, including women of reproductive age, exposure to DOACs in early pregnancy i
Publikováno v:
Thrombosis Research. 182:101-109
Background Depending on test assays and the time of last DOAC intake, direct thrombin inhibitors (DTI) and direct FXa inhibitors (DXI) may or may not affect prothrombin time (PT), international normalized ratio (INR) or activated thromboplastin time
Publikováno v:
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open, Vol 05, Iss 02, Pp e143-e151 (2021)
TH Open, Vol 05, Iss 02, Pp e143-e151 (2021)
The effectiveness and safety of venous thromboembolism (VTE) treatment with apixaban, demonstrated in phase III trials, need to be confirmed in daily care.Using data from the prospective, noninterventional cross-indication Dresden NOAC Registry we ev
Autor:
Luise Tittl, Heike Mizera, Ines Beyer-Westendorf, Ulrike Hänsel, Martin Bornhäuser, Elke Festerling, Thomas Schreier, Sandra Marten, Christiane Naue, Jan Beyer-Westendorf, Marianne Spindler, Antje Reitter
Publikováno v:
Thrombosis research. 190
Edoxaban is licensed in many countries around the world, following successful phase-III trials in stroke prevention in atrial fibrillation (SPAF) and treatment of venous thromboembolism (VTE), but at present, little is known about edoxaban-related bl